Pfizer Inc
NYSE: PFE
$29.42
-$0.24 (-0.8%)
Closing Price on September 20, 2024
PFE Articles
Mylan released its second-quarter financial results before the markets opened on Monday. The pharma giant also announced a major update to its business involving Pfizer and that CEO Heather Bresch is...
Published:
Last Updated:
Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week, including Apple, Exxon and Pfizer.
Published:
Last Updated:
The Dow Jones industrial average in an all-time high territory, and a lot of experts believe it has room to run. But one particular stock is not helping.
Published:
Last Updated:
The July 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Intel, Pfizer and Microsoft above all other Dow stocks.
Published:
Last Updated:
The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
Published:
Last Updated:
Here are five solid defensive picks for investors in what is a very expensive market, and they are also under-owned by active fund managers. All are rated Buy at Merrill Lynch.
Published:
Last Updated:
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Published:
Last Updated:
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Published:
Last Updated:
Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in young children with mild to moderate atopic dermatitis, also known as eczema.
Published:
Last Updated:
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
Published:
Last Updated:
The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Cisco above all other Dow stocks.
Published:
Last Updated:
Running a screen on Finviz reveals that about two-thirds of the Dow’s 30 components are up by double-digit percentages in 2019. Although five of the 30 components still are basically down so far in...
Published:
Last Updated: